CD274 and neoplasm: By first deriving genomic signatures of gene expression responses and DNA methylation for treated NSCLC lines, we observed in most cell lines a complex, multi-faceted up-regulation, involving hundreds of genes of the immune profile of these cells which includes the target of immune checkpoint therapy, the tumor ligand PD-L1.